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 Key points   
Question  Does our group-based lifestyle intervention (with or without trained volunteers with Type 2 diabetes) 
reduce the risk of Type 2 diabetes in people with the current high risk intermediate glycemic categories of 
impaired fasting glucose or non-diabetic hyperglycemia 
Finding In this trial of 1,028 participants with high risk intermediate glycemic categories , the intervention 
significantly reduced the 2 year risk of Type 2 diabetes by 40–47%, although lay volunteer support did not 
reduce the risk further. For every 11 participants treated, one diabetes diagnosis was prevented.   
Meaning Nearly half the adult population  have diabetes or a high risk glycemic category, and this low-cost 
group - delivered intervention significantly reduced the risk of diabetes.   
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Abstract  
Importance  Nearly half the older adult population have diabetes or a high risk intermediate glycemic category 
, but we still lack trial evidence for effective Type 2 diabetes prevention interventions in most of these current 
high-risk glycemic categories.   
Objective  To determine whether our group-based lifestyle intervention (with or without trained volunteers with 
Type 2 diabetes) reduced the risk of progression to Type 2 diabetes in populations with a high risk glycemic 
category 
Design  A parallel, three-arm, group-based, randomized controlled trial, up to 46 month follow–up  (2011- 
2019; Norfolk Diabetes Prevention Study; NDPS).  
Setting  135 primary care practices, and 8 intervention  sites in the East of England. 
Participants We identified 141,973 people at increased risk of Type 2 diabetes, screened 12,778 (9.0%) and 
randomized those with  a high risk glycemic category : either an elevated fasting plasma glucose alone (≥ 110 
and < 126mg/dl) or an elevated glycated hemoglobin (HbA1c; non-diabetic hyperglycemia; NDH; HbA1c ≥ 6.0 
– <6.5%) with an elevated fasting plasma glucose ≥100–< 110 mg/dl),   
Intervention A control arm receiving usual care (CON), a  theory based lifestyle intervention arm of 6 core and 
up to 15 maintenance sessions (INT), or the same intervention with support from diabetes prevention mentors, 
trained volunteers with Type 2 diabetes (INT- DPM).   
Main outcome Type 2 diabetes incidence between arms 
Results We randomized 1,028 participants (INT:424, INT-DPM:426;CON:178) between January, 1st 2011 and   
and February 24th 2017. Mean age (SD) was 65.3 (10) years, mean body mass index 31.2 (5) kg/m2   and 
mean follow-up 24.7 months.  156 participants progressed to Type 2 diabetes: 39/171 (22.8%; CON), 55/403 
(13.7%; INT) and 62/414 (15.0%; INT-DPM). There was no significant difference between intervention arms in 
primary outcome (OR:   1.14; CI 0.77 to 1.7; p=0.51), but each intervention arm had a significantly lower odds 
of Type 2 diabetes   INT: OR 0.54 (CI 0.34-0.85; p=0.008), INT–DPM: OR 0.61(CI 0.39-0.96; p=0.033), 
combined: OR 0.57 (CI 0.38–0.87; p=0.008). Effect size was similar in all glycemic, age, and social deprivation 
groups and intervention costs per participant were low at $153 (£122)   
Conclusion  The NDPS lifestyle intervention reduced the risk of Type 2 diabetes in current  high risk glycemic 
categories. Enhancing the intervention with DPM did not further reduce diabetes risk. These translatable 
results are relevant for current diabetes prevention efforts.   
 
Trial Registration  ISRCTN 34805606. 
Funding   This report presents independent research funded by the National Institute for Health Research 
(NIHR) Programme Grants for Applied Research (RP-PG-0109-10013). The views expressed in this 
publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and 
Social Care.     
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Introduction  
The world diabetes population quadrupled between 1980 and 2014 to 422 million,1 matched by what has been 
described as a worldwide epidemic of the intermediate glycemic  categories that carry a high risk of Type 2 
diabetes .2,3  Nearly half of the older USA and UK population now have Type 2 diabetes or   a high risk 
intermediate glycemic  category,4,5,6 as do a third of young obese adults.7 There is an urgent need for effective 
and affordable diabetes prevention strategies 1,8,9  and national diabetes prevention programs are now  
operating in the USA,10,11  UK,12 and elsewhere.  These offer a  lifestyle intervention to people with a high risk 
score, or  a high risk intermediate glycemic category, with a  plasma glucose or glycated hemoglobin (HbA1c), 
or both that are elevated, but not into the diagnostic range for diabetes.10-12  In the UK, entry to the national  
programme 12, and general recommendations for lifestyle intervention,13 are targeted at people with a high risk  
elevated glycated hemoglobin of ≥ 6.0 – < 6.5% (non-diabetic hyperglycemia; NDH) or an elevated fasting 
plasma glucose  ≥ 100  - < 126mg/dl  (impaired fasting glucose; IFG).14-16   Early observational outcomes are 
encouraging, 10-12 although clinician understanding of diabetes prevention remains poor.17   
   One critically important issue is that the trial evidence for Type 2 diabetes prevention in the now commonly 
used high risk glycemic categories of IFG or NDH is in fact very limited, and this lack of evidence in the current 
high risk phenotypes has been emphasised recently.18  The early landmark prevention trials (used as the 
evidence base for current prevention programs), were mostly in populations defined as high risk  based on an 
impaired glucose tolerance (IGT) category in  a 2 - hour oral glucose tolerance test, rather than a fasting 
plasma glucose and IFG.19-22 The shift to HbA1c criteria , for both categorising  risk   and diagnosing Type 2  
diabetes14-16 then created new large at risk NDH populations. There is as yet no substantial trial evidence for 
benefit from a lifestyle intervention  in people with high risk impaired fasting glucose (IFG) and/or NDH. 18-23   
No prevention trial of more than 2 years duration has used HbA1c as the diabetes diagnostic primary end- 
point, in line with modern diagnostic practice, so the prevention evidence base does not align with current 
diagnostic approaches.18-22  We cannot assume outcomes of earlier  trials (in different high risk glycemic 
populations with IGT), are simply translatable to  populations with current high risk intermediate glycemic 
categories , who differ in pathophysiology, progression rates, and vascular risk.24-27   
  The diabetes prevention benefit found in the  earlier high intensity landmark trials 19-22 has  been much less 
marked in ‘real world’ pragmatic  interventions.28,29  This means that   although there is  a need for lower cost, 
more pragmatic intervention models, the current evidence to support their effectiveness is limited.10-12, 18-23, 28-29  
One attractive option is to include volunteer lay workers, who can support a diabetes prevention intervention 
alongside healthcare professionals to co-deliver an  intervention at potentially lower cost.30-34 People with Type 
2 diabetes themselves are an appealing choice for this role, as they share similar lifestyle challenges to the 
target group. No large controlled trial has tested a diabetes prevention intervention supported by trained lay 
volunteers with Type 2 diabetes , compared to a standard intervention.  
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   In the Norfolk Diabetes Prevention Study (NDPS) we tested the effectiveness of a pragmatic  group - based   
lifestyle intervention, supported by diabetes prevention mentors (trained volunteers with Type 2 diabetes)  
in reducing the incidence of Type 2 diabetes in people with current  prediabetes glycemic categories.   
  
Study design  
 NDPS was a seven year research programme (UK National Institute for Health Research NIHR RP PG 0109 –
10013). The NDPS protocol 35 and baseline publications 35 - 38 summarise NDPS sample sizes, recruitment 
plans, training materials, and screening data.  NDPS identified people with high risk intermediate glycemic 
categories  in the East of England,35 and eligible participants entered  a randomized controlled three-arm 
parallel group trial, with up to 46-month follow-up, testing a group-delivered, theory based, lifestyle intervention, 
with or without the support of trained  lay volunteers (diabetes prevention mentors ; DPM) with Type 2 
diabetes.35,37   
Screening Potential participants were screened with fasting plasma glucose, venous HbA1c, and biometric 
and clinical data collection.35   Participants with an eligible glycemic high risk  category on initial testing  had 
repeat testing a median 40 days (interquartile range 27 - 69 days) later.35,36 Trial randomization was offered if 
paired baseline tests were concordant for a high risk intermediate glycemic category. The first screening 
appointment was August, 22nd, 2011 and last March , 24th , 2017. Protocol driven screening was undertaken by 
NDPS program staff in eight screening sites across the East of England. 35  
 
Inclusion criteria   
Non-diabetic hyperglycemia (NDH) was defined as an HbA1c ≥ 6.0 to < 6.5% 14-16 and impaired fasting glucose 
(IFG) as a fasting plasma glucose (FPG)  ≥ 100 – < 126 mg/dl. 14-16  We defined two study populations with  a 
high risk intermediate glycemic category, based on then current glycemic definitions 14-16 . We randomized 
participants if they had  paired baseline isolated IFG range FPG measurements of  ≥ 110 – < 126 mg/dl, or if 
they had NDH HbA1c combined with IFG FPG ≥ 100 – < 110 mg/dl. 14-16   Initial recruitment (2011- ) into trial 
was for participants with isolated IFG ≥ 110 – < 126 mg/dl. In light of international changes in diabetes 
diagnostic criteria during the program,  the new definition of high risk  NDH, and UK national policy changes 14-
16   we also then randomized those with NDH and a lower range IFG  (≥ 100 – < 110 mg/dl) 14-16  from May, 6th , 
2014. and  also accepted paired HbA1c ≥ 6.5% as a primary end point (as well as paired FPG  ≥ 126 mg/dl) for 
the diagnosis of Type 2 diabetes.14-16,35   IGT during an oral  glucose tolerance test  was not used to randomise 
participants.14-16,35 To identify high risk participants we contacted 194 primary care practices in the East of 
England and 135 (70%) collaborated. We invited all individuals without known diabetes in these practices who 
were a) age ≥ 40 years with a body mass index (BMI) ≥ 30 kg/m2 or b) age ≥ 40 years and BMI ≥ 25 kg/m2 with 
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a recorded first degree family history of Type 2 diabetes, a history of coronary artery disease, or gestational 
diabetes or c) any previous high risk glycemic category diagnosis by recorded category or biochemical range.35  
Ethnicity was participant defined, and this data was collected as important in Type 2 diabetes risk assessment.   
 
Randomization and consent We used a rolling recruitment methodology to randomize participants in parallel 
to the screening programme. Participant screening, recruitment,  and   randomization spanned the study 
duration and continued from August 2011, up until March 24th 2017 and allowed each participant to reach at  
least the six - month time point follow - up appointment , and up to 46 months maximum.  Eligible participants 
were randomized into a control arm (CON) who received no trial intervention, an intervention arm (INT) who 
received a   lifestyle intervention (INT), or into an intervention arm who received the same intervention, but with 
additional telephone support from lay diabetes prevention mentors (INT-DPM). Randomization was conducted 
automatically using a dedicated function in the trial data management system. The randomization mechanism 
consisted of a pre-prepared random list of codes (for the Intervention and control groups) stored in the trial 
database. To reduce the risk of predicting the next allocation while maintaining a reasonable even spread of 
intervention and control patients, the list was constructed of blocks  of 17 codes (3 CON, 7   INT, and 7 INT- 
DPM)  to approximate the proportions of 170:390:390 respectively. Randomization   policies are described in 
Supplement :erandomization and published.35   Randomization was asymmetric between groups to maximize 
sample size and power for comparisons between the intervention groups. Ethical approval was obtained from 
the National Research Ethics Service (NRES), Essex 1 Research Ethics Committee (10/H0301/55; January, 
13th .2011) and all participants  gave written informed consent.  There was no significant clinical trial evidence 
for diabetes prevention benefit with a structured  lifestyle intervention in IFG or NDH subjects at NDPS 
inception, and no UK national prevention programme, and it was ethical to have a control  group who received 
then standard best care.    
                                                                                                                                                                                                                                                                                                                                                       
Interventions The intervention was delivered by trained healthcare professionals alone (diabetes prevention 
facilitators; DPF), or delivered jointly by DPF and DPM.35,37 The intervention theory  aimed to   support 
maintenance of changes in physical activity and diet,  using patient centred counselling techniques to 
encourage decision making about behavior change, increase motivation to change, engage social support, aid 
individually tailored goal setting, action planning and self-monitoring, and support problem solving.35,37   
Behavior change targets were set by  participants, who were encouraged to think about (and presented with 
the health benefits of) 7% weight loss if  BMI  was > 30 kg/m2, achieving 150 minutes per week of moderate 
intensity physical activity over 5 days or more, 2-3 sessions of muscle-strengthening exercise per week, and 
reducing intake of total and saturated fat. The intervention comprised  six 2 -hour educational group sessions 
of varying content for  12 weeks, followed by up to 15 maintenance sessions eight weeks apart from month 4. 
Maintenance sessions were discussion based and followed the same format, including a 50 minute supervised 
physical activity /muscle-strengthening exercise session. Sessions contained no more than 15 participants. 
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The maximum contact time per participant was 49.5 hours. Participants randomized to the INT – DPM   arm 
received additional individual motivational telephone calls between sessions.35,37  DPMs were assigned up to 
seven participants and telephone contacts were monthly for the first 3 months and then every 2 months. During 
these contacts, the DPM and participants discussed progress, goal achievement, action planning, and barriers 
to coping.  INT – DPM   participants therefore received a contact from the study at least every four weeks. 
Control participants (CON) received written information and discussion about the risk of diabetes, and  the 
impact of lifestyle modification on reducing this risk  in line with then current local NHS clinical policy. This was 
delivered in a single 2-hour session delivered by a DPF.35,37   
 
Materials and methods.  Fasting plasma glucose was measured by a hexokinase/G-6-PDH method  (Architect 
c8000: Abbott, Maidenhead, UK).  HbA1c was measured using Affinity high performance liquid 
chromatography (Hb9210: Menarini Diagnostics Ltd., Wokingham, UK).  Additional detail on our methods  and 
materials 38-42 are published 35  and described  in detail in Online Supplement : emethods, which includes a 
fuller description of  measurement of physical activity, homeostasis model assessment (HOMA) of insulin 
sensitivity and beta cell function, and social deprivation scores.    
Outcomes. The primary outcome was the development of Type 2 diabetes based on paired HbA1c data both 
≥ 6.5%, or paired fasting glucose  both ≥ 126 mg/dl. Pre specified secondary outcomes are described 35 and  in 
Supplement : emethods..   
 
Statistical analysis plan and power estimates  The assumed power calculations and sample size estimates   
are summarised in Supplementary material e: statistical analysis plan, The primary statistical analysis 
compared the proportions of participants in each group who progressed to Type 2 diabetes, independent of 
duration of follow-up. We used an intention-to-treat approach to analysis. For binary outcomes we used the 
chi-squared test, and logistic regression for adjustment for baseline imbalances. For continuous outcomes we 
used the t-test for comparison of two arms, or analysis of covariance for comparison of all three, and linear 
regression for adjustment for baseline imbalances. The primary outcome measure was progression to T2DM 
by study exit, analysed using a logistic regression model including a covariate to account for the different 
potential follow-up times at baseline. The full statistical analysis plan, power estimates, sample size, and 
attained power are published 35 and summarised in Supplement e:Statistical analysis plan. We also analysed 
and present the main outcome data using a proportional hazards model as a secondary analysis.   
 
Health economic analysis 
A within-trial analysis was conducted to estimate the cost-effectiveness of the intervention (with and without 
DPM), compared to usual care. 35 These methods are summarised briefly in Supplement e Health Economic 
Analysis, but the full analysis  will be published separately. 
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Results  
 
We invited 141,973 people at increased risk of Type 2 diabetes to participate, and 12,778 (9.0 %) were 
screened.  Between Oct 1st  2011 and June 1st  2017 we randomized 424 eligible participants into the standard 
INT arm,  426  into the  INT – DPM arm,  and 178 into the control arm (CON).  Baseline characteristics and 
flow through the trial are shown (Table 1; Figure 1).  Mean follow up was 742 days (24.7 months), and by arm 
were 727 (CON), 744 (INT), and 746 daysn(INT – DPM). Between 75% and 78% were followed up for at least 
12 months in a rolling recruitment until the end of the recruitment period (Figure 1). There were no significant 
differences between arms in baseline age (p = 0.87) or BMI (p = 0.80) in those who withdrew from intervention.   
 
Of those  who attended at least one intervention session,during follow up, 156 participants progressed to Type 
2 diabetes, 39/171 CON arm (22.8 %; estimated adjusted annual incidence 11.0%), 55/403 INT arm (13.7%; 
estimated adjusted annual incidence :  6.4%) , and 62/414 INT–DPM arm (15.0%; estimated adjusted annual 
incidence adjusted for follow up 7.1%; Supplement : eTable e1).  There was no significant difference between 
intervention arms (INT vs INT – DPM) in the primary outcome (Odds Ratio OR 1.14; 95% CI 0.77 – 1.70; p = 
0.51; Table 2; Figure 2).  
 
There were highly significant reductions in the primary end-point  between each intervention arm compared to 
CON, and between a combined intervention group compared to CON (Tables 2; Figure 2). INT: OR 0.54 (95% 
CI    0.34 – 0.85; p= 0.008), INT – DPM: OR 0.61 (95% CI 0.39 – 0.96; p = 0.033), combined INT and INT–
DPM : OR 0.57 (95% CI 0.38 – 0.87; p = 0.008). The fully adjusted effect size was between a 36 and 42% 
reduction in the odds of Type 2 diabetes (Table 2) depending on arm. These data are shown for our primary 
analysis using a logistic regression model (Table 2) and also a proportional hazards model as a secondary 
analysis (Table 2) 
 
Estimates of differences for the primary outcome of Type 2 diabetes  by subgroup showed no significant 
interactions  with age band, sex, deprivation score, body mass index (BMI), or initial diagnostic category (NDH 
or IFG) in the risk of developing Type 2 diabetes in any arm or the combined group (Table 3). Broadly, one 
participant was prevented from developing diabetes for every 11 intervention participants. 
 
At  12 months  the combined intervention group showed  significantly lower baseline- adjusted  weight (- 
1.76kg ; 95% CI -2.55 to - 0.97; p = 0.01), waist circumference (-2.48 cm, 95% CI -3.67 to -1.29 ; p = < 0.01), 
BMI (- 0.59 kg/m2 ; 95% CI -0.86 to -0.31; p = < 0.01) and greater physical activity (MET mins per week   
p=0.008)   compared to controls (Supplement:  eTable e2), with no significant changes in self-reported dietary 
measures. These differences were apparent for each intervention arm compared to the CON arm. At 24 
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months, lower mean adjusted weight loss in the combined intervention group was maintained (– 1.47 kg ; -2.64 
to –0.30; p = < 0.01)  with highly significant differences in adjusted physical activity compared to controls 
(Supplement: eTable e3). Within the intervention arms, weight loss was particularly marked in the intervention 
subgroup  attained a ‘high dose’ of the intervention compared to those with a low dose at 24 months  (INT  : - 
3.29 ; - -4.97,-1.62; p < 0.001; INT – DPM : - 3.65kg ; -5.99, -1.32; p = 0.002; Supplement:  eTable e4). The  
data on ‘dose response’ effects, unadjusted data, and descriptive data at each time point, are further described 
and shown in Supplement :eResults and Supplement: eTables e5 – e8). Mean intervention costs per 
participant were estimated as $153 (£122)  in the INT arm and $301 (£241) in the INT-DPM arm.  The full 
Health Economic Analysis will be published separately. 
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Discussion.    In this trial, people with a current high risk intermediate glycemic category  of IFG and /or NDH 
were 40 – 47% less likely to develop Type 2 diabetes in the intervention groups  compared to controls, over an 
average  24 months. Broadly, one person was prevented from developing Type 2 diabetes for every eleven 
who received the intervention.  The enhanced intervention with trained Type 2 diabetes volunteers (DPM) did 
not further reduce the risk of Type 2 diabetes.  These findings are relevant to normal clinical practice, as nearly 
half the older adult  population now have a high risk glycemic category or diabetes,4 – 6, 36 as do one- third  of 
obese young adults, with IFG  constituting the largest element.4 - 7 
     NDPS is the largest Type 2 diabetes prevention trial since the US DPP more than 20 years ago 19 - 22 and  
now extends the prevention evidence base to the contemporary high risk  glycemic categories. Nearly all of the 
earlier landmark trial evidence on diabetes prevention  is drawn from people categorised as IGT using an oral 
glucose tolerance test. 19-22 The assumption that this earlier evidence  can simply be translated with  similar 
expected benefit to IFG or NDH   populations with a different phenotype may not be valid.18-23 NDPS now 
provides the reassurance that a low-cost group-based lifestyle intervention in these high risk  groups does 
have a substantial impact in preventing Type 2 diabetes.19 -22  The glycemic criteria we used are those now 
recognised as identifying high risk of diabetes individuals in UK prevention policy, in the NHS England diabetes 
prevention programme, and in  USA prevention programs.10-13  Our results are therefore translatable to the 
current clinical and policy context.  
    Meta - analysis of 11 similar  trials with a diet and physical activity intervention of more than 2 years   in high 
risk glycemic categories  ,20  described a similar composite effect size of RR 0.57 (CI 0.5 to 0.64; p < 0.00001). 
In that  analysis, nine trials 20 exclusively randomized  based on oral glucose tolerance test data, one included 
IFG or IGT, and one included people with a fasting glucose 95 – 124 mg/dl.20,23  None used NDH –IFG  as the  
primary entry  criteria to trial, or HbA1c as  primary end point, in line with current international practice, 
although the US DPP program did analyse HbA1c as a secondary outcome. 43  NDPS effect size did not differ 
significantly in subgroups defined by glycemic category, BMI, age or social deprivation. The only other 
comparable UK clinical trial used oral glucose tolerance testing  as entry criteria and primary end  point, and  
found no overall diabetes prevention benefit other than in a subgroup attaining a higher intervention dose.44,45   
Our full within - trial economic analysis will be published separately, and the high costs of the intense 
interventions in the early landmark research trials are well recognised 46, although intervention models 
translated into clinical settings may be deliverable at lower cost.45,47-49    
       The combined intervention group at 12 months had a significantly lower mean weight (-1.76kg), waist 
circumference (-2.48 cm) and body mass index. Despite relatively low levels of weight loss, compared with the 
landmark studies in the field, the maintenance of behaviour changes or “area under the curve” generated may 
be partly responsible for the high level of impact on diabetes incidence.  For the subgroup who attained a  high 
intervention dose, weight loss was significant even at two years into the programme (- 3.47 kg) compared to 
those attaining a low dose. These weight changes are similar to that seen in systematic analysis of weight loss 
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in intervention arms in both translational and controlled trial prevention studies.28  It is also similar to the 
observed mean weight loss in high attenders the NHS England diabetes prevention  Program (DPP).12   
The  longer term  legacy effect of the NDPS intervention on Type 2 diabetes incidence and maintained weight 
loss is of course unknown, but some short term regain of lost weight after an intensive lifestyle intervention is a 
common observation in people with obesity, Type 2 diabetes, or high risk glycemic categories, particularly in 
those with least initial weight loss.49-52  We also observed a   significant increase in energy expenditure in the 
intervention groups  (e Supplementary material Table 3 – 7).  There is a direct consistent association between 
reduced Type 2 diabetes risk and an increase in almost all type of physical activity and energy expenditure, 
which is only in part mediated through changes in adiposity.53  
   The DPM supplemented intervention group (INT – DPM) did not differ significantly from the standard 
intervention group (INT)  in the risk of Type 2 diabetes, any secondary outcome, or in participant adherence to 
intervention. The use of lay volunteer health workers to deliver lifestyle modification interventions for people at 
high risk of Type 2 diabetes, or with established type 2 diabetes, is well recognised 30-32  but our model did not 
add value. 30-32,37 Only one other study has used people with Type 2 diabetes in this role to prevent diabetes 53 
with  significant improvement in risk markers,  although it is unknown if this translated into a lower Type 2 
diabetes incidence. The impact of lay or peer volunteers on Type 2 diabetes prevention in high risk groups has 
been  reviewed,  with 30 studies (including 10 randomised controlled trials),  largely delivered in high income 
countries to largely non - white minority populations, and studies of between 20 and 2,369 participants. 30 None 
of these   reported a diabetes prevention benefit with diabetes as an endpoint, or were powered to detect such 
an outcome, although there were commonly improvements in surrogate markers for diabetes risk 30 Cluster 
randomised controlled trials in high risk groups using generic lay trainer programmes to support or deliver the 
intervention have also shown no significant impact in diabetes prevention in community or primary care 
settings.32 The NDPS DPM training, levels of retention in programme, responsibilities, and level of contact  
would be regarded as moderate to high compared to other models 30,37. A telephone delivered intervention  as 
we used is as acceptable to participants with NDH as more complex digitally enabled health coaching 54  and  
as effective in risk marker reduction as face to face interventions in people with intermediate high risk of 
diabetes categories. 33,34,55  There is evidence that more frequent contact by telephone peer contact has a 
greater value in reducing Type 2 diabetes risk. 56 In  established T2DM  the frequency of peer contact is a  key 
feature of effectiveness in terms of glycemic change.57 The framework in which the NDPS DPM operated was 
also highly supportive and structured within a multidisciplinary diabetes prevention team, one of the more 
effective ways to use lay volunteers.30,36  We do not think therefore that the the lack of effect our  DPM model is 
due to low intensity DPM training, a short duration of intervention, or an unsupportive framework.30,36 It is 
possible that more intensive contact from the DPM and higher frequency telephone contact may have been 
more effective.  32,33,55,56   It is also quite possible that the lack of DPM effect could be due to the already large 
prevention effect size already attained with the standard intervention alone.   The use of lay trainers (with or 
without Type 2 diabetes) in diabetes prevention remains an attractive model, but the most effective model 
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remains to be determined, and future trials should test different levels of contact intensity,  compare efficacy of 
different lay groups, and using DPM as the primary intervention team.     
      The progression incidence to Type 2 diabetes in the control arm was an adjusted annual 11.9%.  This   is a 
high incidence for these glycemic categories, where very broadly an annual  rate of  5 – 11% has been 
described over 5 years.21  In the US DPP , mean follow up was 2.8 years, and crude incidence rates were 11.0 
cases per 100 participant years in controls, and 4.8 in the lifestyle intervention group. 22   This high rate in 
NDPS reflects our inclusion criteria which were designed to identify and randomise those at highest risk. 35  We 
also excluded lower risk participants with an NDH range HbA1c and a normal fasting glucose < 100 mg/dl. 58  
We also randomized only  those with paired abnormal baseline data at  lower risk of regression to normal 
glycemic status ,35,56,59,60 and we used  both HbA1c and fasting glucose-based  definitions of diabetes for the 
end –point, in line with normal clinical practice. The high progression incidence when “high risk” is categorized 
this way validates the use of this approach in clinical guidelines and in the NHS England  NDPP and   confirm 
the importance of taking action in these high risk groups.12,13   
     At the start of NDPS there was no substantial trial evidence of outcomes benefit from an active lifestyle 
intervention in diabetes prevention in IFG or NDH populations, and NDPS antedated the UK national diabetes 
prevention programme 12 and UK national guidance on best practice in prevention of Type 2 diabetes 13 . 
During NDPS, the control participants received what was (and still is for much  of the population) standard best 
practice UK NHS care for people with a higher risk intermediate glycaemic risk category, with a 2 hour 
education session with a diabetes prevention facilitator to discuss their risk of diabetes and then six month and  
annual review and monitoring. Lifestyle educators are not generally available in practices, and arguably the 
control group received a higher level of support than in normal clinical practice. The original age and BMI 
criteria for screening in NDPS were designed to be concordant with the the UK National Cardiovascular  Risk 
Assessment primary care programme in England 61,62. This   programme started in 2009 , is one of the largest 
cardiovascular risk screening programs in the world, and aims to screen > 3M high risk individuals in primary 
care. There is a substantial glycemic element to the screening, and in 2011 we wished any positive outcomes 
from NDPS to be translatable to the large populations detected in this national programme, and to access 
participants selected in this way as part of normal clinical care.61,62    
  There are limitations in NDPS. The participants come from a largely white population, and results may not be 
translatable to more ethnically diverse populations, or other ethnicities with different patterns of glycemic 
risk.11,12,51,52 This would also apply to adolescent and young adults with a high prevalence of high risk glycemic 
categories,  but where there is no trial evidence for efficacy.6 The attained power and effect size strongly 
support the view that our intervention is effective in diabetes prevention, and while power attained between 
intervention groups analysis was lower, rates of progression were very similar, and any difference is unlikely to 
be meaningful. More than 75% of participants were followed for at least 12 months,  with prolonged follow up  
of  participants recruited earliest, which added  power to the study, and missing data levels were very low.63  
There is a more general observation, common to all similar trials, that wider population level approaches to 
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Type 2 diabetes prevention are needed.64  However, NDPS now extends the diabetes prevention evidence 
base to the modern populations with an at risk glycemic category,18 where trial evidence has been lacking, and 
with an impact on diabetes incidence close to that seen in high intensity clinical trials.18 -20 NDPS confirms that  
prevention efforts in these current high risk  populations  are effective, and brings the evidence base into line 
with current practice.  The glycemic criteria we used are those now recognised as identifying high risk of 
diabetes individuals in UK prevention policy, in the NHS England diabetes prevention programme, in the UK 
national vascular screening program 62 and in  USA prevention programs.10-13  Our intervention materials and 
model are translatable and available to  clinicians in practice, and  suggest that a pragmatic group -based  
lifestyle intervention reduces the risk of Type 2 diabetes in these large populations currently being detected in 
primary care.  
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Figure 1   Trial CONSORT profile (revised and now as a separate document)  
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Table 1. Baseline characteristics of   control  arm  (CON) , standard  intervention arm (INT) , 
and  intervention arm with diabetes prevention ment ors (INT-DPM).  
  
    CON   INT INT-DPM 
n 
 
178   424   426 
Age, mean (SD) , years  
 
65.3 (10.0) 66.5 (8.6 ) 66.7 (9.5) 
Ethnicity White/South Asian/Black/Other (%)  96/1.7/0.6/1.7 97.1/1.7/0/1.2 97.1/1.2/0/1.7 
Sex (n ;%)                                                                  Female   70 (39.3) 166 (39.2) 147 (34.5) 
                                                                                                 Male  108 (60.7 ) 258 (60.8 ) 279 (65.5 ) 
Family history Type 2 diabetes (n ; %)    67 (37.6) 173 (40.8) 167 (39.2 )  
Family history cardiovascular disease (n ; %)    22 (12.4 )  63 (14.9 )  57 (13.4 ) 
Previous gestational diabetes (n; %) a   4 (5.7 ) 12 (7.2) 18 (12.2 ) 
Social deprivation score, mean (SD) b 
 
15.5 (10.6) 15.4 (10.2 ) 16.2 (10.7) 
Weight, mean (SD), kg   90.5 (17.8) 90.2 (18.2) 89.8 (17.4) 
Body mass index, mean (SD), kg/m 2   31.2 (5.0) 31.1 (5.6) 30.9 (5.6 ) 
Waist circumference, mean (SD), cm   105.1 (13.1) 105.1 (13.5) 105.2 (13.0) 
Body fat mass , mean (SD), kg  c   35.2 (8.8) 34.0 (9.0) 33.6 (8.9) 
Impaired fasting glucose (IFG), n (%) d  114 (64.0) 261 (61.6) 256 (60.1) 
Non diabetic hyperglycemia (NDH), n (%) d  64 (36.0) 163 (38.4) 170 (39.9) 
HbA1c, mean (SD), %    6.1 (0.3) 6.1 (0.3) 6.1 (0.3) 
Fasting plasma glucose, mean (SD), mg/dl     
 
112 (7.2) 112 (7.2) 113 (7.2) 
Fasting HDL cholesterol, mean (SD), mg/dl        
 
49.5 (13) 38.7 (13) 38.7 (13) 
Fasting LDL cholesterol, mean (SD), mg/dl 
 
119.1 (35) 117 (34) 118 (35) 
Fasting plasma insulin, mean (SD),  pmol/l)   
 
108.3 (72.5) 95.7  (54.4) 91.0(57.1) 
HOMA insulin sensitivity,  mean (SD),  (%) e 
 
68.5 (41.9 ) 73.2 (51.5) 77.6 (47.2 ) 
HOMA beta cell function,  mean (SD),   (%) e  
 
98.1 (44.0 ) 90.6 (35.6 ) 88.2 (36.3 ) 
Physical activity , mean (SD), MET minutes per week  f 
 
2507 (2761)  2701 (2640)  2660 (2748)  
Physical activity, mean (SD),  minutes sitting per week f  
 
442 (269 ) 463 (263) 431 (241) 
Low physical activity category, n (%) f 
 
42 (32.3)  91 (29.4)  98 (32.3)  
Dietary fat intake scale,  mean (SD)   g  2.3 (0.3 ) 2.3 (0.3 ) 2.3 (0.3 ) 
Wellbeing score (W - BQ12), mean (SD) h   24.8 (6.1) 25.1 (6.5) 25.0 (6.1) 
Health related quality of life score (EQ-5D) , mean  (SD)h   0. 8 (0.2 ) 0.8  (0.2 ) 0.8  (0.2 ) 
 
Data shown as mean and one standard deviation (SD) for continuous variables, or as n (%) for categorical variables.  a Female 
participants,   b  IMD Social Deprivation score 30,   Body fat by Tanita body composition analyser,30  d  Impaired fasting glucose (IFG:   
paired baseline fasting plasma glucose   ≥ 110  – < 126  mg/dl. d Non - diabetic hyperglycemia (NDH) - paired baseline HbA1c   ≥ 6.0 – 
< 6.5 % with IFG fasting plasma glucose ≥ 100  – < 110  mg/dl e Homeostasis model assessment (HOMA) of baseline insulin sensitivity 
(S) and beta cell function (B) expressed as   % of  standard reference range, from fasting plasma insulin and glucose data. 38   f Physical 
activity scales (energy expenditure during physical activity (metabolic equivalent of task (MET) minutes per week),  low physical activity 
category, and sedentary time derived from international physical activity questionnaire IPAQ.39,40   g Dietary fat   and fiber scores based 
on self-reported Diet Behaviour Questionnaire (DBQ).41   h Well - being score (WBQ-12) questionnaire,  health related quality of life 
score (EQ-5D) questionnaire .30,42-44  To convert conventional units to SI unit, for total, HDL and LDL cholesterol (mg/dl) multiply by 
0.0259 (mmol/l ), for plasma glucose (mg/dl) by 0.0555 (mmol/), and glycated hemoglobin (%) by 0.0915IFCC units (mmol/l) + 2.15.  
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Table 2 Estimates of difference between treatment a rms in odds ratio of developing Type 2 
diabetes shown as estimated value and 95% confidenc e interval  and hazard ratio between 
treatment arms in time to developing Type 2 diabete s, shown as estimated value and 95% 
confidence interval in Cox regression models. 
 
 
  
 
  Analysis 
 
INT – DPM 
vs INT   
 
   p 
 
  INT vs    
  CON   
  
    p 
 
INT- DPM   
vs CON   
 
 p 
Combined 
intervention  
vs CON   
 
p 
 
Odds Ratio  
Unadjusted 
 
 
1.11 
(0.75, 1.65) 
 
0.59 
 
0.53 
(0.34, 0.84) 
 
0.007 
 
0.60 
(0.38,0.93) 
 
0.024 
 
0.57 
(0.38, 0.85) 
 
0.006 
 
Odds ratio  
Adjusted a 
 
 
1.12 
(0.75,1.65) 
 
0.59 
 
 
0.54 
(0.34, 0.85) 
 
0.008 
 
0.60 
(0.38, 0.94) 
 
 
0.024 
 
0.57 
(0.38, 0.85) 
 
0.007 
 
Odds ratio  
Adjusted b 
 
1.14 
(0.77,1.70) 
 
0.51 
 
0.54 
(0.34, 0.85) 
 
 
0.008 
 
0.61 
(0.39, 0.96) 
 
0.033 
 
0.57 
(0.38, 0.87) 
 
0.008 
 
Hazard ratio 
Unadjusted 
 
1.09 
(0.76,1.57) 0.63 
0.53 
(0.35,0.80) 0.003 
0.62  
(0.41, 0.92) 0.019 
0.57 
(0.40,0.82) 0.002 
 
Hazard ratio  
Adjusted c 
 
1.13 
(0.78,1.63) 
0.51 0.53 
(0.35,0.81) 
0.003 0.64 
(0.43,0.97) 
0.033 0.58 
(0.41,0.84) 
0.004 
 
 
 
INT : Standard intervention group ; INT – DPM : intervention group with diabetes prevention mentors (DPM) ; COMBINED 
Intervention is  both intervention groups (INT – DPM and INT) combined for comparison against CON; CON : control arm 
without trial intervention. a   adjusted for duration of follow up  b adjusted for follow up length and age, BMI and fasting 
plasma glucose levels at baseline.  c   Adjusted at baseline for age, BMI and fpg levels. Please note the primary analysis 
in NDPS  was a logistic regression model with data presented as odds ratios (above). A  secondary analysis using a  
proportional hazard  model is also shown with hazard ratios (above).  
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Table   3. Estimated odds ratio between treatment a rms of developing Type 2 diabetes by sub groups   :  
age, sex, deprivation score, body mass index, and d iagnostic category shown as odds ratios and 95% 
confidence interval: logistic regression models. 
 
INT – DPM  
vs INT 
  Inter 
 action   
     p 
INT vs CON  
Inter 
action 
p 
INT- DPM  
vs CON   
Inter 
action 
p  
Combined 
intervention  
vs CON  
Inter 
action 
p 
Male 1.07  (0.66, 1.73) 
 
0.83 
0.50  
(0.28, 0.87) 
 
0.68 
0.53  
(0.31, 0.92) 
 
0.54 
0.51  
(0.31, 0.85) 
 
0.58 
Female 
 
1.17  
(0.59, 2.34) 
0.61 
 (0.89, 1.35)  
0.72  
(0.32, 1.57) 
0.66  
(0.32, 1.34) 
Age < 65 years 1.34  (0.71, 2.51) 
 
0.46 
0.47  
(0.23, 0.96)  
 
0.63 
0.63  
(0.31, 1.25) 
 
0.87 
0.55 
 (0.29, 1.03), 
 
0.88 
Age ≥ 65 years 0.99  (0.60, 1.63) 
0.59  
(0.33, 1.06)  
0.58 
 (0.32, 1.05) 
0.58 
 (0.34, 1.00) 
Deprivation  
quartile 1 (low) a 
 
1.49  
(0.62, 3.57) 
 
0.53 
0.54  
(0.20, 1.47)  
 
0.13 
0.80 
 (0.31, 2.09) 
 
0.11 
0.66  
(0.28, 1.59) 
 
0.08 
Deprivation    
quartile 2 
 
0.71 
 (0.35, 1.46) 
0.87  
(0.34, 2.21)  
0.62  
(0.24, 1.59) 
0.73 
 (0.31, 1.73) 
Deprivation 
quartile 3 
1.40  
(0.63, 3.09) 0.80 (0.30, 2.15)  
1.11 
 (0.42, 2.93), 
0.94 
 (0.39, 2.31)  
Deprivation 
quartile 4 (high) 
1.14  
(0.51, 2.50) 
0.23 
 (0.09, 0.53)  
0.26  
(0.11, 0.59) 
0.24 
 (0.11, 0.51) 
BMI quartile 1 b 1.63  (0.72, 3.73) 
 
0.15 
0.42 
 (0.15, 1.14)  
 
0.94 
0.67  
(0.27, 1.71) 
0.45 
0.55  
(0.23, 1.32) 
 
0.89 
BMI quartile 2 1.03  (0.48, 2.21), 
0.62 
 (0.25, 1.49)  
0.63  
(0.26, 1.54) 
0.62  
(0.28, 1.39) 
BMI quartile 3 0.54  (0.24, 1.22) 
0.59  
(0.26, 1.37), 
0.32 
 (0.13, 0.80) 
0.45  
(0.21, 0.97) 
BMI quartile 4 
(high  ) 
1.78 (0.79, 
3.99) 
0.50  
(0.19, 1.31)  
0.88  
(0.36, 2.17) 
0.69  
(0.30, 1.57) 
Impaired fasting 
glucose 
 (IFG) c 
 
0.92  
(0.53, 1.61) 
 
0.35 
0.55  
(0.29, 1.05)  
 
0.89 
0.51 
 (0.26, 0.97)  
 
0.50 
0.53 
 (0.29, 0.95) 
 
0.76 Non-diabetic 
Hyperglycemia 
(NDH) d 
 
1.34  
(0.77, 2.32) 
0.52 
 (0.27, 0.98)  
0.69  
(0.37, 1.28)  
0.60  
(0.34, 1.06)  
 
p value for interaction within each subgroup by arm comparison (INT : Standard intervention  ; INT – DPM : intervention  with diabetes 
prevention mentors (DPM) ; CON: control arm ; COMBINED Intervention is  both intervention groups (INT – DPM and INT) combined 
for comparison against CON;  . b  IMD Deprivation scores 30   b Body mass index (BMI) quartile values are 1: 19 – 27 kg/m2 , 2: 27 to 
30.37 kg/m2, 3: 30.38 to 33.83 kg/m2, 4: 33.86 to 57.65 kg/m2  c Impaired fasting glucose (IFG:   paired baseline fasting plasma glucose   
≥ 110  – < 126  mg/dl. d Non - diabetic hyperglycemia (NDH) - paired baseline HbA1c   ≥ 6.0 – < 6.5 % with IFG fasting plasma glucose 
≥ 100  – < 110  mg/dl  
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Figure  2.     Kaplan-Meier estimate of time to progression by treatment trial arm. 
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1)   e Methods   
Fasting plasma insulin was measured on the Siemens Immulite 2000 XPI (Siemens Healthcare Ltd, Sir William Siemens Square, 
Frimley, Camberley, Surrey.  GU16 8QD), and homeostasi  model assessment (HOMA) of insulin sensitivity and beta cell function 
calculated. 1  Physical activity as an outcome measure was measur d by gathering responses via questionnaire to capture not only 
participants aerobic physical activity but also their r sistance activity.  Aerobic physical activity was measured using the short form 
IPAQ (International Physical Activity Questionnaire 2,3  which gathers information on the intensity of theactivity being engaged in 
(vigorous, moderate or light),  for how long and on how many days of the week,   steps walked and on how may days , and also the 
amount of sedentary activity measured in hours eachd y.  These data were converted to METS or Metabolic Equivalents to express 
the intensity of physical activity 2,3.  Resistance activity was measured by self-report via questionnaire specifically measuring  mode 
and duration of training on how many days of the wek.  Questionnaire measures were administered at follow up time point 
assessments (0, 6, 12, 24,36, 40 months).  In addition to physical activity as an outcome measure, participants attended physical 
activity circuit sessions as part of their maintenance sessions within the intervention.  These session  were 50 minutes duration and 
covered both aerobic and resistance exercises and were delivered by a physical activity facilitator (PAF).  Participants moved around a 
circuit of ‘stations’, with each having a set exercise to perform and up to a choice of 4 levels at which to perform at.  The levels 
represented the intensity of that exercise, allowing participants the opportunity to increase and improve on their performance as their 
intervention progressed.  Participants in the two intervention groups were additionally given a pedometer which showed daily step 
count.  The pedometer was intended as a motivational t ol to encourage an increase in activity. Pedometers were given at the first 
Education session and were retained throughout the study. The data from pedometers was not collected for analysis.  As part of the 
Education phase of the intervention, two sessions fcused specifically on physical activity and part of th se session involved the 
review of a physical activity diary completed by participants over the previous 7 days.  This data was not included for analysis but 
again, allowed the participants to monitor and self-r gulate their exercise behaviour.  Finally, physical activity levels were discussed 
as part of participants progress review section within the intervention sessions and DPM telephone calls.   Physical activity was 
outputs were reported in categories (low, moderate, high activity levels) or as a continuous variable describing the amount of energy 
expenditure during physical activity (metabolic equivalent of task [MET] minutes per week),  as well as the  purpose-made 
questionnaire assessing  frequency of engagement in resistance activity and sedentary time 2,3 Dietary behaviours related to fat and 
fiber intake were assessed using a self-reported Dit Behaviour Questionnaire (DBQ) adapted from an   existing dietary 
questionnaire.4  The WBQ-12 questionnaire was used to measure general w ll-being, including negative well-being, energy and 
positive well-being 5   Health related quality of Life was measured using the validated EQ-5D questionnaire.6,7  Diabetes quality of life 
was assessed using item 1  from the ADDQol questionnaire. 6,7    Measures of deprivation for each participant were derived from 
published indices of deprivation 8  
 
2) e Statistical analysis plan  
The primary and secondary analyses and original statistic l analysis plan have been described 9  . Secondary analyses included a per-
protocol analysis and analysis of secondary outcome measures.   We used multiple  imputation to assess sen itivity of results to 
missing data. A secondary analysis adjusting for potential prognostic factors was agreed prior to the final analysis. Secondary 
continuous outcome measures were analysed using a general linear model in a similar fashion using the lat st measurement at study 
exit as outcome. Time-until progression to T2DM was also analysed using a discrete time survival analysis model. Longitudinal 
analyses of the repeated continuous secondary endpoints were undertaken to assess for differences between arms over time, using a 
random effect approach. Magnitudes of effects were estimated for all two-way comparisons of interventio  groups and no adjustment 
for multiple testing was undertaken. In order to asses  dose-response relationships with between progression and adherence to the 
interventions, analyses were undertaken in each intervention group separately. Four sets of between-group comparisons were made,  
INT-DPM vs INT being the primary comparison, and INT vs CON, INT-DPM vs CON, and INT combined with  INT-DPM vs CON 
being secondary comparisons. The first of these was not adjusted for duration of follow-up, and the second additionally adjusted for 
baseline age and BMI as these were known prognostic var ables. Sensitivity analysis was adjusted for baseline age, BMI and IFG 
levels. Subgroup analyses were conducted separately for gender, age (<65 vs >=65), deprivation quartile, BMI quartile, and baseline 
diagnosis (IFG vs NDH) subgroups, by including subgroup-treatment group interaction terms in the respectiv  models. Secondary 
outcomes were compared at 12 month and 24 month time points using an unadjusted analysis with a two-sample t-test, and an adjusted 
analysis with linear regression models adjusting for baseline values of the respective outcome variables. Secondary outcomes which 
were ordinal were compared using ordinal logistic regression models.  A within-group comparison was made to assess dose-response 
relationships, within each intervention group, as follows. Firstly, an unadjusted analysis was conducted in each group by fitting a Cox-
proportional hazard model for progression and a linear regression model for the other outcomes, with dose the only covariate in the 
model. Secondly, an adjusted analysis was conducted by selecting variables using forward selection. For INT group the ‘dose of 
intervention’ attained was defined as: LOW (less than 30% attendance at sessions), MODERATE ( between  30% and 59% 
attendance), and HIGH (at least 60% attendance at sssions). For the INT – DPM group, these doses wered fined as: LOW ( less than 
30% attendance at sessions regardless of calls conne ted OR less than 30% of calls connected regardless of attendance at sessions); 
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MODERATE (between 30% and 59% attendance at sessions and more than 30% of calls connected or  between 30% and 59% of calls 
connected and more than 30% attendance at sessions);  HIGH  (at least 60% attendance at sessions AND at least 60% of calls 
connected).  We also analysed and present data using a proportional hazards model as a secondary analysis.  The   assumptions 
underlying the original statistical analysis plan,  sample size estimates, and initial  power calculations have been described.8   Original   
power estimates were based on assumed transition raes f om IFG   to T2DM in Northern European white populations, an estimated 
relative risk  of 0.51 after diet and lifestyle  intervention and an 8 % progression rate in CON and a  4% annual progression in the 
INT.8  An original model 36 month intervention asymmetrically randomized controlled trial of 170 controls [CON] and 390 INT 
participants would give 80% power at 5% significance level to detect this difference in proportions progressing. We hypothesized that 
the intervention effect size would be further enhanced by additional support from the DPM and the DPM group would experience a 
T2DM incidence rate of 2% per annum. A group of 390additional participants (INT –DPM) would provide 80% power at 5% 
significance level to detect this difference in proportions progressing between INT – DPM (2%) and INT(4%) arms. When entry to 
trial was extended to include participants with NDH – IFG , progression rate to a Type 2 diabetes diagnosis was assumed to be at an 
annualised transition rate of 7.5% in a CON arm.8 A final accrued sample size of 972, with a maximum 46 month follow up in the 
proposed randomization ratio, gave 99.7% power to de ect this difference between CON and INT, 84% power between CON and INT-
DPM, and 78.6–80.2% power between the two intervention arms.  The power finally attained by the numbers of participants at an 
average follow-up of 24.7 months, at 5% significance level, was 99.4 % (INT vs CON), 80.9 % (INT – DPM vs CON) and 69.1% 
(INT-DPM vs INT).  
 
3)   e Intervention.   
Intervention fidelity was assessed using two main methods.  Firstly, all sessions for all study arms were audio recorded (participants 
consented to this), the recordings were downloaded onto a secured internal hard drive accessible only by intervention staff.  Secondly, 
DPFs were required to complete a checklist at the end of every session reporting on the levels of fidelity reached during that session.  
Checklists were individually tailored for the six Education sessions, control session and a further checklist was developed to be used 
for all 15 Maintenance sessions.  Multiple items were assessed that matched the sections of the session plan documents and depending 
on session, the number of items included on the checklist to assess fidelity ranged from 10-21, on whether they delivered that specific 
component of the intervention 'fully', 'partially' or 'not at -all'.  A comments box was available next to each assessment item.  If the 
answer was 'partially' or 'not at all', the DPF was required to explain why this was the case.  Completion rate for the checklists was 
recorded at 91.7%. During the recruitment period, there was no available structured diet and lifestyle programme for people with high 
risk glycemic categories, and there was no parallel recruitment into the English national prevention programme which started in the 
study area after the NDPS had finished.   
 
4)   eHealth Economic Analysis : methods   
To estimate costs (from a UK National Health Service (NHS) perspective at 2016-17 prices), those who delivered the intervention 
recorded the resource use (time inputs) associated wi h the training, education and maintenance session , plus ongoing 
supervision/support.  Additionally, all participants were asked to complete a self-report health servic  use questionnaire at 6, 12, 24 
and 40 month time points.9  Unit costs were assigned to each item of resource se.10-13  Additional DPM costs included training, a 
telephone charge cost for each call and DPM supervision, as well as a single honorarium payment of £350 for each DPM. 
Effectiveness was estimated based on the clinical primary outcome (progression to Type 2 DM) and cost- per quality adjusted life year 
(QALY) analysis  based on EQ-5D-3L.14-16  Incremental  costs per T2DM progression averted and incremental cost per QALY were 
estimated over a 24 month follow-up period, where costs and QALYs incurred after 12 months were discounted at 3.5% and multiple 
imputation was used to estimate missing data. 16-18 Bivariate regression analysis  was undertaken and the incremental cost-
effectiveness ratios (ICER : mean incremental cost/mean incremental effect)  estimated. Please note on 1.31.17 conversion rate was 
£1GBP to $1.25 USD, and equivalent conversion rate on 1.30.20 was £1GBP to $1.30 USD. The full results of these analyses will be 
reported separately.  
 
5)   e Randomization.    
Randomization procedure was conducted by a DPF during a 30 minute individual appointment, and randomization of participants 
conducted automatically using a dedicated function in the trial data management system. The randomization mechanism consisted of a 
pre-prepared random list of codes (for the Intervention and control groups) stored in the trial database. To reduce the risk of predicting 
the next allocation while maintaining a reasonable ev n spread of intervention and control patients, the list was constructed of blocks  
of 17 codes (3 CON, 7   INT, and 7 INT- DPM)  to approximate the proportions of 170:390:390 respectively.  Ethical approval was 
obtained from the National Research Ethics Service (NRES), Essex 1 Research Ethics Committee (10/H0301/55; 3.1.2011).   
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6)  e Results  and response by dose of intervention 
Of 424 INT participants, 125 (29.7%), 77 (18.2%) and 221 (52.1%) respectively received low, medium andhigh doses of the 
intervention. Of 426 INT-DPM participants, 135 (31.7%), 107 (25.1%) and 184 (43.2%) respectively received low, medium and high 
doses of the intervention. Compared to the equivalent groups (within INT or INT-DPM) who attained a low dose exposure to the 
intervention, the high dose exposure groups at 12 months had highly significant adjusted reductions in mean HbA1c, weight, and 
fasting plasma glucose (Table 7). This significant effect was maintained for weight loss in the high dose group at 24 months for both 
groups (INT  : - 3.44kg ; - 5.51,-1.37; p = 0.001; INT – DPM : - 3.65kg ; -5.99, -1.32; p = 0.002),  compared to the low dose attained 
group,  indicating that a significant and clinically meaningful effect on weight was maintained at 2 years (Table 7). There was no 
significant difference in primary outcome by dose attained however, with 11/126 (8.7%) low dose and 32/221(14.4%) high dose 
participants in the INT arm developing diabetes (adjusted odd ratios compared to low dose 1.72 [95%CI  0.54  , 5.46). The equivalent 
data for the INT – DPM arm were 21/135 (15.5%) and 28/184 (15.2%).  
 
 
  
 
 
 
 
 
         eTable 1 Percentage of individuals who progressed t o Type 2 diabetes in each arm  
 
. 
  CON    INT   INT – DPM  
Progression 39/ 178 (21.9%) 55 / 424 (13.0%) 62 / 426 (14.6%) 
Progression (excluding those 
with no follow-up data) * 39/ 171 (22.8%) 55/ 403 (13.7%) 62 / 414 (15.0%) 
 
 
CON: control arm without trial intervention,   INT :  standard intervention group , INT – DPM :  intervention group with additional diabetes prevention 
mentors . * No post baseline biochemical data. 
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eTable 2.  Differences between trial arms at 12 mon ths : adjusted mean differences (95% CI) in 
linear regression models  
 
Analysis INT-DPM    vs INT 
 
p 
INT vs CON  
p 
INT- DPM  
vs CON 
 
p 
Combined 
INT v CON 
 
p 
 
HbA1c, % 
0.01 
(-0.47, 0.5)  0.95  
-0.64 
 (-1.3, 0.02)  0.06 
-0.6  
(-1.25, 0.05)  0.07 
-0.63 
 (-1.2, -0.04)  0.04 
Fasting plasma 
glucose, mg/dl 
-0.02 
(-0.11, 0.07) 
0.68 -0.02 
 (-0.13, 0.09)  
0.71  -0.04  
(-0.15, 0.08)  
0.54 -0.03 
 (-0.13, 0.07)  
0.6 
 
Weight, kg 
-0.39 
(-1.06, 0.28) 
0.26 
-1.56  
(-2.39, -0.74)  
 0.001 
-1.96 
 (-2.85, -1.06)  
 0.001 
-1.76 
 (-2.55, -0.97)  
 0.001 
Body mass index,    
kg/m 2 
-0.13 
(-0.36, 0.1) 
0.25  
-0.52  
(-0.81, -0.23)  
 0.001 
-0.66  
(-0.97, -0.35), 
 0.001 
-0.59 
 (-0.86, -0.31)  
 0.001 
 
Body fat , % a   
-0.56  
(-1.02, -0.11) 0.01  
-0.31  
(-0.88, 0.26)  0.29 
-0.88 
 (-1.48, -0.27), 0.005 
-0.58  
(-1.13, -0.04)  0.034 
 
Body fat mass,kg  a 
-0.84 
(-1.57, -0.12)  
0.02  -0.51 
 (-1.34, 0.32)  
0.23 -1.45  
(-2.39, -0.5), 
0.003 -0.98 
 (-1.82, -0.14)  
0.022 
Waist 
circumference, cm 
-0.25 
(-1.14, 0.64)  
0.58  
-2.36  
(-3.72, -1), 
0.001 
-2.59  
(-4.02, -1.17), 
 0.001 
-2.48 
 (-3.67, -1.29)  
 0.001 
 
MET mins / week b 
1.21 
(-603.8, 606 ) 0.99  
905.5  
(209.7, 1601 ) 0.01  
914.8 
(159.9, 1669.6 )  0.018 
915.5   
(235, 1596)  0.008 
Physical activity    
category b 
1.05  
(0.69, 1.62)  
0.81  2.19  
(1.29, 3.71)  
0.004 2.43 
 (1.4, 4.23), 
0.002 2.27 
 (1.39, 3.7) 
0.001 
 
Resistance days/wk  
b 
0.97 
 (0.63, 1.5)  
0.90  
2.34 
 (1.25, 4.38)  
0.008 
2.25 
 (1.22, 4.16), 
0.009 
2.29 
 (1.29, 4.06) 
0.005 
 
Minutes sitting/wk b 
1.21 
 (-603 , 606 )  
0.99  
905.5  
(210, 1601 )  
0.01  
914.8  
(160, 1670)  
0.018 
915.55  
(235, 1596)  
0.008 
 
Fat scale score c 
0  
(-0.06, 0.05)  0.94  
0.02  
(-0.05, 0.09)  0.52  
0.02  
(-0.05, 0.09)  0.56 
0.02  
(-0.04, 0.09)  0.51  
 
Fiber scale score c 
-0.02 
 (-0.09, 0.05), 
0.53  
0.04 
 (-0.04, 0.12) 
0.34 
0.01 
 (-0.07, 0.1)  
0.75 
0.03  
(-0.05, 0.11)  
0.52 
 
WBQ - 12  d 
-0.16  
(-0.98, 0.67)  
0.71  
0.92 
 (-0.14, 1.98)  
0.09 
0.86  
(-0.26, 1.97)  
0.13  
0.92 
 (-0.05, 1.89)  
0.06  
 
EQ – 5D d 
0.01  
(-0.02, 0.03)  0.70  
-0.01  
(-0.05, 0.02)  0.46  
-0.01  
(-0.04, 0.02)  0.586 
-0.01  
(-0.04, 0.02)  0.47 
 
ADDQoL d 
0.05  
(-0.1, 0.19)  0.50  
0.18  
(0, 0.36)  0.06 
0.22  
(0.02, 0.42)  0.028 
0.2 
 (0.03, 0.37)  0.021 
 
HOMA – B (%) e 
0.17  
(-3.77, 4.12)  
0.93  
-0.69 
 (-5.36, 3.98)  
0.77  
-1.29 
 (-6.87, 4.29)  
0.65 
-0.95 
 (-5.63, 3.73)  
0.69 
 
HOMA – S (%) e 
4.21  
(-3.88, 12.3)  0.31 
1.28 
 (-7.99, 10.54)  0.79 
5.02 
 (-6.09, 16.12)  0.38 
3.24 
 (-6.17, 12.66)  0.50 
 
Data shown as change in mean and 95% CI.   INT : Standard intervention arm ; INT – DPM : intervention  arm with diabetes prevention mentors (DPM) ; 
Combined intervention : both intervention groups combined; CON : no trial intervention.   Fat mass (kg and %) by Tanita body composition analyser.9 a   
Physical activity scales (energy expenditure during physical activity [metabolic equivalent of task (MET) minutes per week] , resistance - questionnaire 
assessment of frequency of   resistance activity (days per week), and  low physical activity category, and sedentary time  from international physical 
activity questionnaire IPAQ. 2,3,9, b    Dietary fat   and fiber  scores based on self-reported Diet Behaviour Questionnaire (DBQ). 4, c  d Well - being score 
(WBQ-12) questionnaire 5,6 ,d  , health related quality of life score (EQ-5D) questionnaire 6,d  and ADDQoL  first question.7,d    Homeostasis model 
assessment (HOMA) of baseline insulin sensitivity (S) and beta cell function (B)  as  % of  standard reference range. 1,9,e   To convert conventional units to 
SI unit,  for plasma glucose (mg/dl) multiply by 0.0555 (mmol/l), and glycated hemoglobin (%) by 0.0915 IFCC units (mmol/mol) + 2.15. Please note 
reference number sequence relates  to reference list in Supplementary Online material.      
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eTable 3.  Differences between trial arms at 24 mon ths - adjusted mean differences (95% CI) in 
linear regression models  
 
Analysis INT-DPM  vs INT 
 
p 
INT vs CON  
p 
INT- DPM 
 vs CON 
 
p 
Combined 
INT v CON 
 
p 
 
HbA1c, %  
-0.03 
 (-0.69,0.62) 0.92  
-0.72 
 (-1.66,0.22) 0.13  
-0.77 
 (-1.69,0.14) 0.09  
-0.74  
(-1.57,0.1) 0.08  
Fasting plasma 
glucose, mg/dl  
0.04  
(-0.07,0.16) 0.47  
-0.12  
(-0.27,0.03) 0.11  
-0.07  
(-0.24,0.1) 0.41  
-0.09  
(-0.24,0.05) 0.21 
 
Weight, kg  
-0.39 
 (-1.35,0.56) 0.42 
-1.28  
(-2.54,-0.02) 0.05 
-1.66 
 (-2.93,-0.4) 0.01 
-1.47  
(-2.64,-0.3) 0.01  
Body mass index,    
kg/m 2 
-0.16 
 (-0.49,0.17) 0.35 
-0.42 
 (-0.87,0.02) 0.06 
-0.6 
 (-1.04,-0.16) 0.008 
-0.5 
 (-0.91,-0.1) 0.01  
 
Body fat , %  a 
-0.5 
 (-1.13,0.12) 0.11  
-0.02 
 (-0.82,0.78) 0.96 
-0.56 
 (-1.41,0.29) 0.20 
-0.28  
(-1.05,0.48) 0.47 
 
Body fat , kg  a 
-0.68 
 (-1.53,0.17) 0.12 
-0.3 
 (-1.44,0.84) 0.61 
-1.01  
(-2.1,0.07) 0.07 
-0.65  
(-1.68,0.39) 0.22  
Waist 
circumference, cm  
-1.52 
 (-3.05,0.01) 0.05  
-0.79  
(-3,1.42) 0.48  
-2.31 
 (-3.75,-0.87) 0.002 
-1.56 
 (-3.4,0.2) 0.09 
 
MET mins / week b 
179.8  
(-670,1029 ) 0.68 
911.6  
(-196 , 2019 ) 0.11 
1075.3 
 (-4.2, 2154 ) 0.05  
985.8  
(-36 , 2008) 0.06 
Physical activity    
category b 
1.22  
(0.7,2.14) 0.48 
2.05 
(1.01,4.13) 0.05 
2.52  
(1.22,5.2) 0.01  
2.24 
(1.15,4.37)   0.02 
 
Resistance days/wk  
b 
1.1  
(0.62,1.96) 0.74  
4.37 
(1.46,13.11) 0.008 
5.11 
(1.82,14.36) 0.002 
4.77 
(1.73,13.16) 0.003 
 
Minutes sitting/wk b 
-26.9 
 (- 85, 32) 0.37 
-8.09  
(-89.0 ,72.8 ) 0.84  
-31.1  
 (-108.4,46.2) 0.43 
-21.43 
 (-93.1 ,50.3) 0.56 
 
Fat scale score c 
-0.01 
 (-0.09,0.07) 0.78 
0.11 
 (0.01,0.2) 0.03 
0.1  
(-0.01,0.2) 0.07  
0.1 
 (0.01,0.19) 0.03 
 
Fiber scale score c 
-0.01 
 (-0.1,0.09) 0.9 
0.12 
 (0,0.24) 0.04  
0.1  
(-0.02,0.22) 0.10  
0.11  
(0,0.22) 0.06 
 
WBQ - 12  d 
0.14 
 (-1.02,1.31) 0.81  
0.91  
(-0.56,2.38) 0.22  
1.05 
 (-0.45,2.55) 0.17 
0.98  
(-0.36,2.33) 0.15  
 
EQ – 5D d 
-0.02 
 (-0.07,0.02) 0.26 
-0.01 
 (-0.06,0.03) 0.57  
-0.04  
(-0.09,0.02) 0.22  
-0.02  
(-0.07,0.02) 0.32  
 
ADDQoL d 
-0.03 
 (-0.23,0.17) 0.74  
0.06 
 (-0.18,0.3) 0.67 
0.02 
 (-0.23,0.28) 0.85 
0.04 
 (-0.19,0.27) 0.72  
 
HOMA – B (%) e 
-3.77 
 (-8.34,0.81) 0.11 
1.02 
 (-5.31,7.35) 0.75  
-2.88  
(-9.56,3.8) 0.40 
-0.87 
 (-6.72,4.97) 0.77 
 
HOMA – S (%) e 
1.04  
(-10.8,12.4 ) 0.86 
8.5  
(-4.2, 21.1) 0.18 
10.5 
(-4.9,26 ) 0.18  
9.36 
 (-4.06,22.8) 0.17  
 
Data shown as change in mean and 95% CI.  INT: Standard intervention arm ; INT – DPM : intervention  arm with diabetes prevention mentors (DPM) ; 
Combined intervention : both intervention groups combined; CON : no trial intervention.   Fat mass (kg and %) by Tanita body composition analyser. 9 a   
Physical activity scales (energy expenditure during physical activity [metabolic equivalent of task (MET) minutes per week] , resistance - questionnaire 
assessment of frequency of   resistance activity (days per week), and  low physical activity category, and sedentary time  from international physical 
activity questionnaire IPAQ. 2,3,9, b    Dietary fat   and fiber scores based on self-reported Diet Behaviour Questionnaire (DBQ). 4, c  d Well - being score 
(WBQ-12) questionnaire 5,6 ,d  , health related quality of life score (EQ-5D) questionnaire 6,d  and  ADDQoL first question.7,d    Homeostasis model 
assessment (HOMA) of baseline insulin sensitivity (S) and beta cell function (B)  as % of  standard reference range. 1,9,e   To convert conventional units 
to SI unit,  for plasma glucose (mg/dl) multiply by 0.0555 (mmol/l), and glycated hemoglobin (%) by 0.0915 IFCC units (mmol/mol) + 2.15. Please note 
reference number sequence relates to reference list in Supplementary Online material.  
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              eTable 4.  Descriptive data for outco mes at 12 months by trial arm  
 
Analysis CON     n INT     n  INT- DPM     n 
 
HbA1c, mean (SD), % 6.0  (0.4) 135 6.0 (0.4) 304 6.0 (0.4 ) 305 
Fasting plasma glucose, mean 
(SD),  (mg/dl) 108 (11) 135 108 (10 ) 303 108 (11) 304 
 
Weight, mean (SD),  kg  87.2 (16.5 ) 
135 
 
85.6 (16.3 ) 304 84.5 (16.20) 300 
Body mass index, mean (SD),  
kg/m 2  30.0 (4.7) 128 29.4 (5.03) 304 29.1 (5.05) 300 
 
Body fat, mean (SD), %  a 30.61 (10.6) 128 28.70 (11.3) 
 
297 
 
28.07 (11.2) 292 
 
Body fat, mean (SD),  kg  a 34.8 (8.41) 128 33.0 (8.9) 
 
297 
 
32.7 (9.0) 292 
 
Waist circumference, mean SD, 
cm  
103.2 (14.3) 135 101.2  (12.8 ) 304 100.9 (12.6 ) 301 
 
MET mins / week, mean (SD) b 2974 (3065) 90 3679 (3011) 221 3869 (3295) 187 
Low Physical activity category,  
n (%) b 25 (27.8) 90 36 (16.3) 221 27 (14.4) 187 
Resistance ( 0 – 1 days / week), 
                        n (%)  b 63 (73.3) 86 120 (57.1) 210 114 (57.6) 198 
 
Minutes sitting/wk, mean (SD)  b 424 (284) 99 390  (232) 226 374 (242) 205 
 
Fat scale score, mean (SD)   c 2.35 (0.35) 105 2.39 (0.38) 235 2.39 (0.40) 226 
 
Fiber scale score, mean (SD)   c 2.40 (0.37) 106 2.48 (0.40) 233 2.42 (0.43) 224 
 
W - BQ12 mean (SD), d 25.7  (6.9 ) 97 26.8(6.2) 224 26.6  (5.5) 212 
 
EQ – 5D, mean (SD), d 0.03 (0.15) 94 -0.00 (0.15) 196 0.01 (0.14) 195 
 
ADDQoL. mean (SD), d 1.4  (0.9 ) 101 1.6 (0.9 ) 235 1.6 (0.96) 222 
 
HOMA – B, mean (SD), % e 89.0 (39) 129 82.6 (33) 296 81.0 (33) 284 
 
HOMA – S, mean (SD),   %  e 86.3  (57 ) 129 92.1 (56 ) 296 98.6(64) 284 
 
Data shown as  mean and 1SD.  INT: Standard intervention arm  ; INT – DPM : intervention  arm with diabetes prevention mentors (DPM) ; Combined 
intervention : both intervention groups combined; CON : no trial intervention.   Fat mass (kg and %) by Tanita body composition analyser. 9 a   Physical 
activity scales (energy expenditure during physical activity [metabolic equivalent of task (MET) minutes per week] , resistance - questionnaire assessment 
of frequency of   resistance activity (days per week), and  low physical activity category, and sedentary time  from international physical activity 
questionnaire IPAQ. 2,3,8, b    Dietary fat   and fiber scores based on self-reported Diet Behaviour Questionnaire (DBQ). 4, c  d Well - being score (WBQ-12) 
questionnaire 5,6 ,d  , health related quality of life score (EQ-5D) questionnaire 6,d  and  ADDQoL  first question.7,d    Homeostasis model assessment (HOMA) 
of baseline insulin sensitivity (S) and beta cell function (B)  as % of  standard reference range. 1,9,e   To convert conventional units to SI unit,  for plasma 
glucose (mg/dl) multiply by 0.0555 (mmol/l), and glycated hemoglobin (%) by 0.0915 IFCC units (mmol/mol) + 2.15. Please note reference number 
sequence relates to reference list in Supplementary Online material.       
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                eTable 5. Descriptive data for outc omes at 24 months by trial arm 
 
Analysis CON    n INT n INT- DPM n 
 
HbA1c, mean (SD), % 6.1 (0.4) 75 6.1 (0.3) 186 6.0 (0.3) 192 
Fasting plasma glucose, mean (SD),  
(mg/dl) 110  (11 ) 75 108  (10 ) 186 110 (11) 190 
 
Weight, mean (SD),  kg  85.8  (16.0) 75 85.78 (16.9 ) 186 84.4 (17.2 ) 191 
Body mass index, mean (SD),  kg/m 2  29.8  (4.7) 75 29.5 (5.3 ) 186 29.8 (5.1) 190 
 
Body fat, mean (SD), %  a 33.7  (8.6 ) 71 33.5  (9.1 ) 176 32.0 (9.1) 185 
 
Body fat, mean (SD),  kg  a 29.2 (10.0 ) 71 29.3  (12.3 ) 176 27.51 (11.3) 185 
 
Waist circumference, mean SD, cm  102.9 (12 ) 75 102.8 (15) 185 100.6  (13.2) 190 
 
MET mins / week, mean (SD) b 
2746 
(2957) 
49 3677 (3411) 128 4290 (3658) 128 
Low Physical activity category,  
n (%) b 15 (30.6) 49 20 (15.6) 128 15 (11.7) 128 
Resistance ( 0 – 1 days / week), 
                        n (%)  b 44 (86.3) 51 80 (62.0) 129 74 (55.6) 133 
 
Minutes sitting/wk, mean (SD)  b 425 (280) 
 
55 
 
405  (237) 134 362 (231) 140 
 
Fat scale score, mean (SD)   c 2.3  (0.4) 61 2.4  (0.4) 141 2.4  (0.4 ) 147 
 
Fiber scale score, mean (SD)   c 2.3 (0.4 ) 61 2.5 (0.4 ) 139 2.4  (0.5) 147 
 
W - BQ12 mean (SD), d 26.4  (5.27) 58 26.9  (5.5) 137 26.8  (5.8) 143 
 
EQ – 5D, mean (SD), d 0.02 (0.14) 56 0.00 (0.15) 117 -0.03 (0.21) 128 
 
ADDQoL. mean (SD), d 1.53 (0.8 ) 60 1.61 (0.9 ) 142 1.52 (1.0 ) 152 
 
HOMA – B, mean (SD), % e 86.7 (39 ) 71 78.6  (30) 178 74.3 (33) 180 
 
HOMA – S, mean (SD),   %  e 83.6 (53 ) 71 96.3 (57 ) 178 103.5 (70) 180 
 
Data shown as   mean and 1SD.  INT: Standard intervention arm  ; INT – DPM : intervention  arm with diabetes prevention mentors (DPM) ; Combined 
intervention : both intervention groups combined; CON : no trial intervention.   Fat mass (kg and %) by Tanita body composition analyser.9 a   Physical 
activity scales (energy expenditure during physical activity [metabolic equivalent of task (MET) minutes per week] , resistance - questionnaire assessment 
of frequency of   resistance activity (days per week), and  low physical activity category, and sedentary time  from international physical activity 
questionnaire IPAQ. 2,3,9, b    Dietary fat   and fiber scores based on self-reported Diet Behaviour Questionnaire (DBQ). 4, c  d Well - being score (WBQ-12) 
questionnaire 5,6 ,d  , health related quality of life score (EQ-5D) questionnaire 6,d  and  ADDQoL  first question.7,d    Homeostasis model assessment (HOMA) 
of baseline insulin sensitivity (S) and beta cell function (B)  as % of  standard reference range. 1,9,e   To convert conventional units to SI unit,  for plasma 
glucose (mg/dl) multiply by 0.0555 (mmol/l), and glycated hemoglobin (%) by 0.0915 IFCC units (mmol/mol) + 2.15. Please note reference number 
sequence relates to reference list in Supplementary Online material.  
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e Table 6 :  Differences between trial arms at 12 m onths - unadjusted mean differences (95% 
CI) in linear regression models  
 
    Analysis INT-DPM vs 
INT     p 
INT vs CON     p INT- DPM  vs CON      p 
Combined 
INT v CON    p 
 
HbA1c, %  
0.01 
(-0.04, 0.0.06) 
0.77 
 -0.03 
(- 0.1,0.03) 
0.32 
- 0.03 
(- 0.1, 0.04) 
0.43 
-0.03 
 (- 0.1,0.03) 
0.32 
Fasting plasma 
glucose, mg/dl  
-0.7 
(- 2.3, 0.05) 0.42 
0.0 
(- 2.2 , 1.9) 0.93 
- 0.7 
(- 2.5 , 1.4) 0.5 
-  0.4 
(- 2.4 , 1.4) 0.67 
 
Weight, kg  
-1.15 
(-3.76,1.45) 
0.38 -1.58 
(-4.91,1.76) 
0.35 -2.73 
(-6.1, 0.59) 
0.11 -2.15 
(-5.2,0.9) 
0.17 
Body mass index,    
kg/m 2 
-0.32 (-
1.13,0.48) 
0.43 
-0.61 
(-1.61,0.39) 
0.23 
-0.93 
(-1.93,0.08) 
0.07 
-0.77 
(-1.7,0.16) 
0.11 
 
Body fat , %  a 
-0.29 
(-1.74,1.16) 
0.7 
-1.84 
(-3.66,-0.02) 
0.05 
- 2.13 
(-3.96,-0.3) 
0.02 
-1.98 
(-3.68,-0.29) 
0.02 
 
Body fat , kg  a 
-0.63 
(-2.45,1.19) 0.5 
-1.92 
(-4.23,0.4) 0.1 
-2.55 
(-4.84,-0.25) 0.03 
-2.23 
(-4.36,-0.1) 0.04 
Waist circumference, 
cm  
-0.32 
(-2.3 ,1.7 ) 
0.76 -1.95 
(-4.7 ,0.7 ) 
0.16 -2.27 
(-4.9 ,0.4 ) 
0.1 -2.11 
(-4.5 ,0.3 ) 
0.09 
 
MET mins / week b 
190 
(-423 ,804 ) 
0.54 704   
(-39 ,1449 ) 
0.06  895   
( 81 ,1709) 
0.03  792  
(76 ,1507 ) 
0.03 
Physical activity    
category b 
1.13 
(0.78,1.63) 
0.51  1.83 
(1.15,2.9) 
0.01 2.07 
(1.29,3.33) 
0.003   
1.94 
(1.26,2.98) 
0.002 
 
Resistance days/wk  b 1.03 (0.7,1.51) 0.89 
2.05 
(1.19,3.54) 
0.01 
2.07  
(1.2,3.58) 
0.009 
2.06 
(1.23,3.43) 
0.006 
 
Minutes sitting/wk b 
-15.4 
 (-59.8,28.9 ) 0.50 
-34.5 
 (-93.2 ,24.3) 0.25 
-49.9 
 (-111.3 ,11.6) 0.11  
-41.8   
(-95.4 ,11.8 ) 0.126 
 
Fat scale score c 
0 
(-0.07,0.07) 
0.99 0.04 
(-0.05,0.12) 
0.39 0.04 
(-0.05,0.13) 
0.41 0.04 
(-0.04,0.12) 
0.36 
 
Fiber scale score c 
-0.05 
(-0.13,0.02) 
0.17 0.07 
(-0.02,0.16) 
0.11 0.02 
(-0.08,0.12) 
0.68 0.05 
(-0.04,0.13) 
0.28 
 
WBQ - 12  d 
0.02 
(-0.88,0.92) 
0.96 
0.75 
(-0.35,1.84) 
0.18 
0.77 
(-0.42,1.95) 
0.2 
0.76 
(-0.27,1.79) 
0.15 
 
EQ – 5D d 
0.01 
(-0.02,0.04) 
0.34 
-0.03 
(-0.07,0.01) 
0.11 
-0.02 
(-0.05,0.02) 
0.38 
-0.02 
(-0.06,0.01) 
0.17 
 
ADDQoL d 
0.1 
(-0.06,0.27) 
0.22 0.17 
(-0.04,0.37) 
0.11 0.27 
(0.04,0.5) 
0.02 0.22 
(0.02,0.41) 
0.03 
 
HOMA – B (%) e 
-1.54 
(-7.03,3.9 ) 0.58 
-6.48 
(-13.7,0.78) 0.08 
-8.02 
(-15.4 ,-0.63) 0.03 
-7.23 
(-13.8,-0.63) 0.03 
 
HOMA – S (%) e 
6.5 
(-3.3,16.3) 
0.19 5.75 
(-6.0 ,17.5) 
0.34 12.25 
(-0.62, 25.1) 
0.06 8.94 
(-2.4 , 20.3) 
0.12 
 
Data shown as   mean and 1SD.  INT: Standard intervention arm  ; INT – DPM : intervention  arm with diabetes prevention mentors (DPM) ; Combined 
intervention : both intervention groups combined; CON : no trial intervention.   Fat mass (kg and %) by Tanita body composition analyser. 9 a   Physical 
activity scales (energy expenditure during physical activity [metabolic equivalent of task (MET) minutes per week] , resistance - questionnaire assessment 
of frequency of   resistance activity (days per week), and  low physical activity category, and sedentary time  from international physical activity 
questionnaire IPAQ. 2,3,9, b    Dietary fat   and fiber scores based on self-reported Diet Behaviour Questionnaire (DBQ). 4, c  d Well - being score (WBQ-12) 
questionnaire 5,6 ,d  , health related quality of life score (EQ-5D) questionnaire 6,d  and  ADDQoL  first question.7,d    Homeostasis model assessment (HOMA) 
of baseline insulin sensitivity (S) and beta cell function (B)  as % of  standard reference range. 1,9,e   To convert conventional units to SI unit,  for plasma 
glucose (mg/dl) multiply by 0.0555 (mmol/l), and glycated hemoglobin (%) by 0.0915 IFCC units (mmol/mol) + 2.15. Please note reference number 
sequence relates to reference list in Supplementary Online material.  
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eTable 7 Differences between trial arms at 24 month s - unadjusted mean differences (95% CI) 
in linear regression models  
 
       Analysis INT-DPM  vs INT 
 
p 
INT vs CON  
p 
INT- DPM  
vs CON 
 
p 
Combined 
INT v CON 
 
p 
 
HbA1c, %  
0.02 
(- 0.04, 0.1) 0.47 
-0.06 
(-0.17, 0.3) 0.19 
- 0.04 
(- 0.14,0.06) 0.41 
- 0.05 
(- 0.14, 0.34) 0.23 
Fasting plasma 
glucose, mg/dl  
0.4 
(-0.1, 0.14) 
0.7 
- 1.4 
(- 4.1, 7.3) 
0.28 
- 1.1 
(- 4.1 , 2.0) 
0.5 
- 1.3 
( - 4.0, 1.4) 
0.35 
 
Weight, kg  
-1.39 
(-4.85,2.07) 
0.43 
-0.06 
(-4.55,4.42) 
0.98 
-1.46 
(-5.99,3.07) 
0.53 
-0.77 
(-4.97,3.43) 
0.72 
Body mass index,    
kg/m 2 
-0.78 
(-1.83,0.27) 0.15 
-0.27 
(-1.66,1.11) 0.7 
-1.05 
(-2.38,0.27) 0.12 
-0.67 
(-1.94,0.6) 0.3 
 
Body fat , %  a 
-1.52 
(-3.4,0.37) 
0.11 
-0.22 
(-2.71,2.27) 
0.86 
-1.73 
(-4.19,0.72) 
0.17 
-1.0 
(-3.3,1.31) 
0.4 
 
Body fat , kg  a 
-1.8 
(-4.25,0.64) 0.15 
0.12 
(-3.11,3.36) 0.94 
-1.68 
(-4.7,1.34) 0.27 
-0.8 
(-3.75,2.15) 0.59 
Waist 
circumference, cm  
-2.16 
(- 5.0 ,0.66) 0.13 
-0.13 
(-3.9,3.6 ) 0.95 
-2.3 
(-5.8,1.2) 0.19 
-1.23 
(-4.6 ,2.2) 0.48 
 
MET mins / week b 
612   
(-258,1483 ) 0.17 
931  
(-161 ,2022 ) 0.09   
1543  
(389 ,2697 ) 0.009 
1237.23 
(176.36,229
8.1) 
0.02  
Physical activity    
category b 
1.41 
(0.88,2.25) 0.15 
2.18 
(1.16,4.07) 0.01  
3.04 
(1.61,5.75) 0.001 
2.58 
(1.44,4.62) 0.001 
 
Resistance days/wk  
b 
1.31 
(0.81,2.12) 0.27 
3.52 
(1.47,8.43) 0.005 
4.58 
(1.92,10.89) 0.001 
4.08 
(1.77,9.4) 0.001 
 
Minutes sitting/wk b 
-41.96 
 (-97.4 ,13.6) 0.14 
-21  
(-99.9 ,57.9 ) 0.6 
-63.0 
 (-140  ,14.1) 0.11 
-42.4 
 (-112.8 ,28 ) 0.24 
 
Fat scale score c 
0 
(-0.1,0.09) 
0.92 0.08 
(-0.03,0.2) 
0.13 0.08 
(-0.05,0.21) 
0.21 0.08 
(-0.03,0.19) 
0.14 
 
Fiber scale score c 
-0.04 
(-0.14,0.06) 0.45 
0.15 
(0.03,0.27) 0.02 
0.11 
(-0.02,0.25) 0.1 
0.13 
(0.01,0.25) 0.03 
 
WBQ - 12  d 
0.1 
(-1.23,1.43) 
0.88 0.88 
(-0.83,2.6) 
0.31 0.98 
(-0.74,2.7) 
0.26 0.94 
(-0.62,2.49) 
0.24 
 
EQ – 5D d 
-0.01 
(-0.23,0.22) 
0.95 0.04 
(-0.22,0.3) 
0.76 0.03 
(-0.25,0.32) 
0.82 0.04 
(-0.22,0.29) 
0.78 
 
ADDQoL d 
-0.03 
(-0.08,0.02) 0.21 
-0.02 
(-0.06,0.03) 0.45 
-0.05 
(-0.11,0.01) 0.13 
-0.03 
(-0.08,0.02) 0.21 
 
HOMA – B (%) e 
-4.28 
(-10.82,2.26) 
0.2 -8.0 
(-17.14,1.14) 
0.09 -12.3 
(-21.8,-2.76) 
0.01 -10.2 
(-18.5 ,-1.8) 
0.02 
 
HOMA – S (%) e 
7.22 
(-6.1 ,20.5 ) 
0.29 12.7 
(-2.9 ,28.2 ) 
0.11 19.9 
(1.7 , 38.0 ) 
0.03 16.3 
(0.3 ,32.2) 
0.05 
 
Data shown as   mean and 1SD.  INT: Standard intervention arm  ; INT – DPM : intervention  arm with diabetes prevention mentors (DPM) ; Combined 
intervention : both intervention groups combined; CON : no trial intervention.   Fat mass (kg and %) by Tanita body composition analyser. 9 a   Physical 
activity scales (energy expenditure during physical activity [metabolic equivalent of task (MET) minutes per week] , resistance - questionnaire assessment 
of frequency of   resistance activity (days per week), and  low physical activity category, and sedentary time  from international physical activity 
questionnaire IPAQ. 2,3,9, b    Dietary fat   and fiber scores based on self-reported Diet Behaviour Questionnaire (DBQ). 4, c  d Well - being score (WBQ-12) 
questionnaire 5,6 ,d  , health related quality of life score (EQ-5D) questionnaire 6,d  and  ADD QoL  first question.7,d    Homeostasis model assessment 
(HOMA) of baseline insulin sensitivity (S) and beta cell function (B)  as % of  standard reference range. 1,8,e   To convert conventional units to SI unit,  for 
plasma glucose (mg/dl) multiply by 0.0555 (mmol/l), and glycated hemoglobin (%) by 0.0915 IFCC units (mmol/mol) + 2.15. Please note reference number 
sequence relates to reference list in Supplementary Online material.  
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e Table 8  Change in mean  weight, fasting plasma g lucose, and HbA1c at 12 and 24 months 
by participants achieving higher ‘doses’ of interve ntion (moderate, or high) compared to 
lowest dose participants, shown for both  intervent ion arms  (mean (95% CI)  
 
12 months  
GROUP:    INT   INT –DPM  
 
  
Moderate 
Dose 
 
p High 
Dose 
p Moderate 
Dose 
p High 
Dose 
p 
HbA1c, %  
Unadjusted 
-0.1 
(- 0.12, 0.02) 
0.10 
- 0.14 
(- 0.22, -0.05) 
 
0.002 
-0.1  
(- 0.17, 0.01) 0.07  
-0.15  
(- 0.22 , -0.1) 0.001 
HbA1c,  % 
Adjusted 
- 0.11 
(- 0.26, 0.02) 
0.10 
- 0.17 
(- 0.28 ,-0.06) 
0.004 
- 0.02 
 (- 0.23, 0.01) 
0.06 
- 0.16 
 (- 0.01 , -0.05) 
0.003 
Weight (kg) 
Unadjusted 
-1.32 
(-2.75, 0.12) 0.07 
-2.05 
(-3.19,-0.91) <0.001 
-1.05 
 (-2.5,0.4) 0.16 
-2.12 
 (-3.38,-0.85) 
 
0.001 
Weight (kg) 
Adjusted 
-1.30 
(-3.31, 0.7) 
0.20 
-2.20 
(-3.82,-0.57) 
0.008 
-1.46 
 (-3.4,0.43) 
0.13 
-2.72 
 (-4.4,-1.04) 
0.002 
Fasting plasma 
glucose, mg/dl 
Unadjusted 
0 
(- 3.6 , 3.6) 
0.99 
- 1.1 
(- 3.6 , 1.8) 
0.49  
- 1.8 
 (- 5.4, 0.11) 
0.35 
- 4.5 
 (-7.6, -1.3) 
0.006 
Fasting plasma 
glucose, mg/dl 
Adjusted 
- 2.3 
(- 6.8 , 2.2) 
0.30 - 2.8 
(- 6.9 ,0.9) 
0.14  - 3.4 
 (- 7.6 , 0.9) 
0.11 - 5.4 
 (- 9.0 ,- 1.6) 
0.004 
  
                                                                                             24 months 
HbA1c, %  
Unadjusted -0.04 
(- 0.17, 0.1) 
0.55 
- 0.21 
(- 0.32, - 0.1) 
<0.001 
- 0.07 
(- 0.18, 0.05) 
0.27 
- 0.001 
 (- 0.2, 0.1) 
0.54 
HbA1c,  % 
Adjusted 0.01 
(- 0.14, 0.2) 
0.77 
- 0.15 
(- 0.3, -0.001) 
0.05 
-0.1 
(- 0.19, 0.02) 
0.10  
-0.04 
 (-0.17, 0.1 ) 
0.55  
Weight (kg) 
Unadjusted -1.79 
(-3.81, 0.22) 
0.08 -3.29 
(-4.97,-1.62) 
0.001 -2.33 
 (-4.17,-0.49) 
0.01  -2.78 
 (-5.1, -0.46) 
0.02 
Weight (kg) 
Adjusted -0.67 
(-3.47, 2.13) 0.65  
-3.65 
(-5.99, -1.32) 0.002 
-2.97 
 (-4.6,-1.34) 0.001 
-3.44  
(-5.5 , -1.37) 0.001  
Fasting plasma 
glucose, mg/dl 
Unadjusted 
0.5 
(- 4.1, 4.5) 0.82 
0.7 
(- 3.24 , 9) 0.72  
- 0.7 
(- 5.8, 4.3) 0.79 
- 1.1  
(-6.4, 4.4) 0.68  
Fasting plasma 
glucose, mg/dl 
Adjusted 
0 
(- 6.1,6.1) 
0.99 
- 0.18 
(- 5.1, 5.0) 
0.92  
- 2.3  
(- 6.4, 2.2) 
0.30 
- 0.7 
 (- 5.8, 4.4) 
0.78  
 
 INT : Standard intervention group ; INT – DPM : intervention group with diabetes prevention mentors (DPM). To convert conventional units to SI unit,  
for plasma glucose (mg/dl) multiply by 0.0555 (mmol/l), and glycated hemoglobin (%) by 0.0915 IFCC units (mmol/mol) + 2.15 (if > 3.0%).   
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